Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (71-80 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology and Therapy|February 20, 2022
Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid ArthritisRoy Fleischmann, Kyle Hayes, Sung-Woo Ahn, et al.
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
The Journal of Rheumatology|November 3, 2016
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing SpondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
RMD Open|April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease durationMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Clinical Pharmacokinetics|October 11, 2016
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid ArthritisEun Bong Lee, Nikki Daskalakis, Christine Xu, et al.
Arthritis Research & Therapy|August 25, 2021
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL StrategyTsutomu Takeuchi, Roy Fleischmann, Noriko Iikuni, et al.
Annals of the Rheumatic Diseases|August 22, 2014
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?Roy Fleischmann, Désirée van der Heijde, Andrew S Koenig, et al.
RMD Open|July 25, 2024
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYONDRonald F van Vollenhoven, Stephen Hall, Alvin F Wells, et al.
Arthritis and Rheumatism|June 10, 2004
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsMichael H Schiff, Gino DiVittorio, John Tesser, et al.
Pageof 19

Showing results (71-80 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology and Therapy|February 20, 2022
Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid ArthritisRoy Fleischmann, Kyle Hayes, Sung-Woo Ahn, et al.
Rheumatology and Therapy|December 19, 2022
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus MethotrexateRoy Fleischmann, Boulos Haraoui, Maya H Buch, et al.
The Journal of Rheumatology|November 3, 2016
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing SpondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
RMD Open|April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease durationMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Clinical Pharmacokinetics|October 11, 2016
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid ArthritisEun Bong Lee, Nikki Daskalakis, Christine Xu, et al.
Arthritis Research & Therapy|August 25, 2021
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL StrategyTsutomu Takeuchi, Roy Fleischmann, Noriko Iikuni, et al.
Annals of the Rheumatic Diseases|August 22, 2014
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?Roy Fleischmann, Désirée van der Heijde, Andrew S Koenig, et al.
RMD Open|July 25, 2024
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYONDRonald F van Vollenhoven, Stephen Hall, Alvin F Wells, et al.
Arthritis and Rheumatism|June 10, 2004
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsMichael H Schiff, Gino DiVittorio, John Tesser, et al.
Pageof 19